Skip to main content
Equibles
INO logo

INO · Inovio Pharmaceuticals, Inc.

Track INO — free

Use INO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about INO

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.09 +0.19 (+21.10%) At close · Aug 14
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Customer concentration — top customer 100% of revenue

One customer — 100% of revenue (the years ended December 31, 2025 and 2024)

“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
View the 10-K filed Mar 12, 2026
Market Cap
$112.70M
Shares
103.40M

Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.

Filed Type Offering Sold
2020-01-24 New $4,040,590 $4,040,590
Showing 1–1 of 1 filings
Key facts CIK 1055726 CUSIP 45773H409 13F (30d) 103 filings 101 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)